TRDA Entrada Therapeutics Inc. Total Asset Value of Company

This daily price action for Entrada Therapeutics (TRDA) on GURU.Markets reflects total assets amounting to 373.80. The business relies on a universal method for transporting biologics into cells, which streamlines the mass production of numerous drugs. Payments from global behemoths for access to this technology are currently supporting the growth. However, success is complicated by development challenges and a dependence on new investments.

TRDA (Entrada Therapeutics) Company Total Assets history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Entrada (TRDA)

- market value and analyst target forecast:

Stock Price entradatx.com|TRDA - Price Target Chart

- market capitalization data:

Market Valuation Entrada Therapeutics, Inc|TRDA - Enterprise Value

- issuer book value statistics:

Accounting Value of a Share Entrada Therapeutics|TRDA - Book Capitalization|Market Capitalization to Book Value Ratio entradatx.com|TRDA - Aggregate Company Assets

- debt burden and liquidity indicators:

All Debt to Shareholders' Equity Ratio Entrada Therapeutics|TRDA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Entrada Therapeutics, Inc|TRDA - Company Aggregate Debts|Debts to Book Capitalization Entrada Therapeutics, Inc|TRDA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Entrada Therapeutics|Immediate Liquidity Ratio entradatx.com

- net income and valuation multiples indicators:

TRDA - Net Profit

Fundamental valuation:Entrada Therapeutics

Manufactured products of Entrada Therapeutics

Entrada Therapeutics investors are anticipating the monetization of the EEV platform amid stringent FDA oversight. Total assets, calculated inversely via ROA, measure the aggregate resource potential and financial stability of the business. According to the total asset calculation on GURU.Markets, the current value is 373.80. This volume of capital ensures the protection of intellectual property and covers the costs of complex clinical trials for neurological drugs.

Key competitors

jazzpharma.com (JAZZ) - Company Total Assets|Aggregate Company Assets Cytokinetics, Incorporated|PTC Therapeutics Inc - Total Asset Value of Company|Company Total Assets SRRK|CNTA (Centessa Corp) - Aggregate Asset Value|Company Total Assets DYN (Dyne Therapeutics, Inc.)|Company Total Assets edgewisetx.com EWTX|RAPP - Aggregate Company Assets|Aggregate Asset Value ALMS (Alumis Inc)|Kempharm (ZVRA) - Aggregate Company Assets|Cumulative Company Assets Contineum Corp|LRMR (Larimar Therapeutics) - Company Total Assets|Company Total Assets Capricor|Cumulative Company Assets PTHS (Channel Therapeutics Corp)|MNOV (medicinova.com) - Aggregate Asset Value|Aggregate Company Assets Serina SER|BTAI: Total Business Assets|ProMIS - Company Total Assets|Company Assets Apimeds Pharmaceuticals|AEON (aeonbiopharma.com) - Cumulative Company Assets|NLS Pharmaceutics (NLSP) - Company Total Assets|Aggregate Company Assets Bionomics Ltd.|HUGE: Aggregate Asset Value|Aggregate Company Assets Reata Pharmaceuticals (RETA)